RecruitingNCT06228677

Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization

Comparison of Catecholamine Concentrations in Adrenal Venous Blood and Peripheral Venous Blood During Percutaneous Selective Adrenal Artery Embolization in Hypertensive Patients With Primary Aldosteronism: A Prospective Cohort Study

Sponsor

First Affiliated Hospital of Chengdu Medical College

Enrollment

196 participants

Start Date

Sep 18, 2023

Study Type

OBSERVATIONAL

Conditions

Primary Aldosteronism Secondary Hypertension Resistant Hypertension Secondary Hypertension to Endocrine Disorders

Summary

To explore the relationship between perioperative blood pressure and catecholamine concentrations in adrenal venous blood and peripheral venous blood in hypertensive patients with primary aldosteronism (PA) who underwent percutaneous selective adrenal artery embolization (SAAE). In order to elucidate the related phenomena and possible mechanisms of blood pressure fluctuations caused by SAAE treatment in hypertensive patients with PA.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

Age ≥18 years with no gender restrictions.
Adherence to the "Primary Aldosteronism" Diagnosis and Treatment Guidelines, confirmed diagnosis of primary aldosteronism following rigorous drug washout, and identification as either aldosteronoma or idiopathic aldosteronism via adrenal vein blood sampling.
Blood pressure metrics that satisfy any of the subsequent conditions: a) Clinic-recorded blood pressure ≥140/90mmHg; b) 24-hour ambulatory blood pressure monitoring results displaying average blood pressure \>130/80 mmHg or daytime readings \>135/85 mmHg.
Adrenal CT scan revealing adrenal hyperplasia, nodular formations, or no significant morphological deviations.
Hypertension history surpassing a duration of 6 months.
Prior to screening, patients or their lawful guardians must provide a signed informed consent, sanctioned by the ethics committee.

Exclusion Criteria7

Patients diagnosed with primary hypertension or secondary hypertension attributed to other etiologies.
Female participants who are presently pregnant, lactating, or with intentions to conceive within the forthcoming year.
Presence of significant systemic diseases, with particular attention to hepatic and renal dysfunction.
Pronounced allergic reaction to contrast agents.
Any other serious systemic diseases with a life expectancy of less than 12 months.
Participants concurrently enrolled or expressing interest to participate in other clinical trials, the outcomes of which could potentially influence the results of the current study.
The researcher's discretion deems the subject inappropriate for inclusion in the study for any given reason.